Oncology

News

Ibrance cleared in US for 'double-positive' breast cancer

Ibrance has become the first CDK4/6 inhibitor to be approved for a challenging subtype of breast cancer that is often resistant to current treatment.

News

NICE delivers more good news for cervical cancer patients

Hundreds of women with locally advanced cervical cancer are to be offered MSD's Keytruda on the NHS in England, thanks to new NICE guidance.

News

Astellas' Padcev and Gilead's Trodelvy grab key EU approvals

New approvals in the EU for Astellas' Padcev and Gilead's Trodelvy break new ground in the treatment of bladder and triple-negative breast cancer.

News

Image of a pair of lungs on an orange-beige background

Pfizer's Seagen-derived ADC pipeline suffers a setback

One of the antibody-drug conjugates at the heart of Pfizer's $43bn acquisition of Seagen three years ago has failed a phase 3 lung cancer trial.

News

CARSgen bags world-first approval for solid tumour CAR-T

CARSgen Therapeutics has claimed approval in China for gastric cancer therapy satri-cel, the first CAR-T to be cleared for a solid tumour.

Oncology

ASCO 2026 reshapes oncology trial design

The American Society of Clinical Oncology 2026 annual meeting showcased how, across tumour types, new cancer therapies are achieving deeper responses, extending survival and increasingly mo

Ibrance cleared in US for 'double-positive' breast cancer

NICE delivers more good news for cervical cancer patients

Astellas' Padcev and Gilead's Trodelvy grab key EU approvals

Pfizer's Seagen-derived ADC pipeline suffers a setback

CARSgen bags world-first approval for solid tumour CAR-T

ASCO 2026 reshapes oncology trial design

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

Oncology

Editor's Picks